Asthma Drugs Market Trends, Business Growth and Major Driving Factors 2028

Asthma is a lung disease that affects people of all ages. It produces wheezing and makes breathing difficult. Exposure to an allergy or irritant, infections, exercise, emotional stress, and other conditions are all potential triggers. When the symptoms of asthma become unbearable, an asthma attack ensues. Attacks can happen out of nowhere and range from mild to life-threatening. Asthma is managed with rescue inhalers to treat symptoms and controller inhalers that prevent symptoms. Severe cases may require longer-acting inhalers that keep the airways open (formoterol, salmeterol) and inhalant steroids. Asthma medication comes in several forms, including tablets, injections, liquids, and inhalers, and it falls into two groups, such as bronchodilators and anti-inflammatories.

Grab PDF to Know More (Including Table, Full TOC and Figures) @ https://www.theinsightpartners.com/sample/TIPRE00021879/?utm_source=OpenPR&utm_medium=10209

AstraZeneca; TEVA PHARMACEUTICAL INDUSTRIES LTD; GlaxoSmithKline plc; Boehringer Ingelheim International GmbH; Merck & Co., Inc; Koninklijke Philips N.V.; Sanofi; Pfizer Inc. (Arena Pharmaceutical GmbH); Novartis AG; and Abbott are a few leading companies operating in the global asthma drugs market.

According to our latest study, "Asthma Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Medication, Route of Administration, and Distribution Channel," the asthma drugs market size is projected to grow from US$ 24,239.17 million in 2021 to US$ 34,136.10 million by 2028; it is estimated to grow at a CAGR of 5.0% from 2021 to 2028. The report highlights the key factors driving the market and prominent players with their developments. The growth of the asthma drugs market is primarily attributed to the growing environmental implications & genetic implications of air pollution and more vulnerability in specific ethnic groups. On the other hand, unmet medical needs and lack of treatment adherence hinder the market's growth.

The report segments the Asthma Drugs market as follows:

Based on medications, the asthma drugs market is bifurcated into quick relief medications and long-term control medications. Based on route of administration, the asthma drugs market is segmented into inhaled, prefilled syringe/vials, and others. Based on distribution channels, the asthma drugs market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. By geography, the asthma drugs market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Speak to Analyst for more details: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00021879?utm_source=OpenPR&utm_medium=10209

The COVID-19 pandemic diverted resources from healthcare services for patients with diseases such as asthma. COVID-19 causes lung dysfunction, complicating asthma treatment. With an outbreak of COVID-19 in most countries globally, modifications to asthma management have been adopted to accommodate the crisis and minimize the exposure of asthma patients to the infection. As per a research article, International Archives of Allergy and Immunology 2021, the analysis results are in contrast with recently published data from NHS England. In a report of 5,683 COVID-19-linked deaths, the authors reported a higher probability of death in asthmatics with (hazard ratio= 1.25; 95% CI 1.08-1.44) and without corticosteroid use (hazard ratio= 1.11; 95% CI 1.02-1.20).

Based on route of administration, the asthma drugs market is segmented into inhaled, prefilled syringe/vials, and others. In 2021, the inhaled segment held the largest share of the market; however, prefilled syringe/vials segment is estimated to register the highest CAGR of 7.4% in the market during the forecast period. Asthma inhalers are the most popular and effective method of administering asthma medication into the lungs. They come in various shapes and sizes and work in various ways. Some only provide one type of drug, and others have two drugs. There are two types of inhalers, including metered-dose inhalers and dry powder inhalers. A metered-dose inhaler is a device that employs a small aerosol canister to deliver a short burst of medication through a mouthpiece made of plastic. A dry powder inhaler that only releases medicine when you inhale deeply. Moreover, various companies are launching inhalers for the treatment of asthma. For instance, on 15th June 2021, a drug firm named Glenmark Pharma announced the launch of Bromide Fry Powder Inhaler, which is used to treat chronic obstructive pulmonary disease, in the UK. Moreover, Chronic obstructive pulmonary disease (COPD) is a long-term condition that causes inflammation in the lungs, damaged lung tissue, and a narrowing of the airways, making breathing difficult. Glenmark Pharmaceutical is the only company to launch an equivalent version of the Bromide dry powder inhaler under the brand name Tiogiva in the UK for the treatment of COPD.

Directly Purchase Premium Copy of Asthma Drugs Market Growth Report: https://www.theinsightpartners.com/buy/TIPRE00021879/?utm_source=OpenPR&utm_medium=10209

Contact US

Contact Person : Sameer Joshi .

Phone : +1-646-491-9876

E-mail : sales@theinsightpartners.com

About US

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

This release was published on openPR.